XML 55 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1

Development, Commercialization and Supply Agreement - Additional Information (Detail)	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) Item	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments						$ 598,000
Licenses revenue				$ 55,323,000	$ 47,360,000	151,884,000	$ 127,238,000
Deferred revenue				20,956,000		20,956,000		$ 19,054,000
Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue				350,000	$ 309,000	598,000	895,000
Mochida | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment						$ 2,700,000
Eddingpharm | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received			$ 15,000,000
Number of indications of the regulatory milestone events relating to the submission and approval | Item						3
Amounts to be received upon achievement of the regulatory milestone events						$ 33,000,000
Sales-based milestone event payment						120,000,000
Revenue recognized related to upfront and milestone payments						100,000	900,000
Deferred revenue				$ 13,200,000		$ 13,200,000		12,900,000
Revenue recognized over remaining period				16 years		16 years
Eddingpharm | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue						$ 2,800,000		3,100,000
Eddingpharm | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone						153,000,000
Amounts to be received upon achievement of the regulatory milestone events						15,000,000
Sales-based milestone event payment						50,000,000
Eddingpharm | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events						2,000,000
Sales-based milestone event payment						5,000,000
Eddingpharm | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment		$ 1,000,000
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment		10 years
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received	$ 5,000,000
Non-refundable milestone payment	$ 2,500,000
Revenue recognized related to upfront and milestone payments						500,000
Deferred revenue				$ 6,800,000		$ 6,800,000		4,900,000
Revenue recognized over remaining period				12 years		12 years
Non-refundable up-front received period	6 months
HLS | Out-licenses | Other Receivables
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment						$ 2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue						$ 700,000		$ 100,000
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone	$ 57,500,000
Revenue recognized related to upfront and milestone payments							$ 100,000

X

- Definition

Estimated number of days following the end of the quarter before related revenue is recognized.

+ References

No definition available.

+ Details

Name:	amrn_DeferredRevenueRecognitionPeriod
Namespace Prefix:	amrn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Eligible milestone payment.

+ References

No definition available.

+ Details

Name:	amrn_EligibleMilestonePayment
Namespace Prefix:	amrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Eligible regulatory milestone event payment.

+ References

No definition available.

+ Details

Name:	amrn_EligibleRegulatoryMilestoneEventPayment
Namespace Prefix:	amrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Eligible sales based milestone event payment.

+ References

No definition available.

+ Details

Name:	amrn_EligibleSalesBasedMilestoneEventPayment
Namespace Prefix:	amrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

License And Collaboration Agreements [Line Items]

+ References

No definition available.

+ Details

Name:	amrn_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix:	amrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Non-refundable and non-creditable upfront payment.

+ References

No definition available.

+ Details

Name:	amrn_NonRefundableAndNonCreditableUpfrontPayment
Namespace Prefix:	amrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non refundable upfront payments received.

+ References

No definition available.

+ Details

Name:	amrn_NonRefundableUpfrontPaymentsReceived
Namespace Prefix:	amrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Non refundable upfront payments received period.

+ References

No definition available.

+ Details

Name:	amrn_NonRefundableUpfrontPaymentsReceivedPeriod
Namespace Prefix:	amrn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Nonrefundable milestone payment.

+ References

No definition available.

+ Details

Name:	amrn_NonrefundableMilestonePayment
Namespace Prefix:	amrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number of regulatory milestone events indications.

+ References

No definition available.

+ Details

Name:	amrn_NumberOfRegulatoryMilestoneEventsIndications
Namespace Prefix:	amrn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_MochidaPharmaceuticalCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrn_InLicensesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrn_OutLicensesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=amrn_ClinicalTrialApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_BiologixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_HLSTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BalanceSheetLocationAxis=amrn_OtherReceivablesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: